Telbivudine
Mechanism :
Telbivudine is a nucleoside analog reverse transcriptase inhibitor. It works by blocking the growth of the hepatitis B virus (HBV).
Indication :
- Chronic hepatitis B infection.
Contraindications :
Allergic to any ingredient in telbivudine.
Enlarged liver or high levels of lactic acid in the blood.
Peginterferon alfa-2a.
Dosing :
16 years or older: 600 mg orally once a day.
Adverse Effect :
Chills, cough, diarrhea, fever, discomfort, headache, joint pain, loss of appetite, muscle aches and pains, nausea, sweating, insomnia, weakness.
Interaction :
Peginterferon alfa-2a: Using telbivudine together with peginterferon alfa-2a is generally not recommended. Combining these medications may increase the risk and/or severity of nerve damage.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 30-50 | 600 mg every 48 hours |
| <30 | 600 mg every 72 hours |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Dialysed. 600 mg every 96 hours |
| HD | Dialysed. 600 mg every 96 hours |
| HDF/High flux | Dialysed. 600 mg every 96 hours |
| CAV/VVHD | Dialysed. Dose as in GFR<30 mL/min |
Hepatic Dose :
No dose adjustment recommended.